Advertisement · 728 × 90
#
Hashtag
#caxtx
Advertisement · 728 × 90
Post image

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

2 0 0 0
Post image

Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified

3 0 0 0
Program Guide – ASCO Meeting Program Guide

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505
meetings.asco.org/abstracts-pr... #mmsm #caxtx

3 0 0 0
Program Guide – ASCO Meeting Program Guide

Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx

2 0 0 0
Program Guide – ASCO Meeting Program Guide

Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx

2 0 0 0
Post image

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

2 1 0 0
Post image

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

2 0 0 0
Post image

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

2 0 0 0
Post image

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

7 1 0 0
Post image Post image

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

3 0 1 0
Post image Post image Post image

Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark RCTs in Relapsed/Refractory Multiple Myeloma [Sep 2019] @AjaiChari et al. CLML ow.ly/L23c30qmAT2 #mmsm #ClinicalTrials #caxtx

0 0 0 0
Post image Post image

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis [Oct 10, 2023] @GemmaKReynolds et al. @benwteh @BloodAdvances ashpublications.org/bloodadvance... #IDonc #mmsm #caxtx

4 1 0 0
Redirecting

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients [Sep 6, 2023] @benwteh et al. @TheLancetInfDis doi.org/10.1016/S147... #IDonc #leusm #lymsm #mmsm #mpnsm #caxtx

0 0 0 0
Post image

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

1 0 0 0
Post image

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

7 4 0 0
Post image

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

9 3 0 1
Post image

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

4 1 0 0
Post image

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

2 0 0 0
Redirecting

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients [Sep 6, 2023] @benwteh et al. @TheLancetInfDis doi.org/10.1016/S147... #IDonc #leusm #lymsm #mmsm #mpnsm #caxtx

6 0 0 0